Biogen IDEC - Product Websites Zevalin ® (ibritumomab tiuxetan) On February 19, 2002, the Food and Drug Administration (FDA) approved Zevalin for marketing in the U.S.Zevalin is indicated for the treatment of relapsed or refractory low grade, follicular, or transformed B-cell non-Hodgkin's lymphoma (NHL) including patients with Rituxan®) (rituximab) refractory...
Biogen Idec - Customer Support Insurance specialists help patients taking AVONEX® (Interferon beta-1a), RITUXAN® (rituximab), ZEVALIN ® (ibritumomab tiuxetan) and AMEVIVE® (alefacept) with insurance coverage issues.
Biogen Idec - Products on the Market home | contact info | locations | site map investor relations | careers Company Products - Products on the Market - Product Development - Science - Manufacturing Patients Products on the Market TYSABRI® (natalizumab) Please click here for the Dear Healthcare Professional Letter Regarding TYSABRI®.
Biogen Idec - Company home | contact info | locations | site map investor relations | careers Company + Management - Vision and Values + Investor Relations + News and Media - Corporate Governance + Careers - History - New Ventures + Strategic Alliances + Community Relations Products Patients About Biogen Idec Biogen Idec Inc.
Biogen Idec - History home | contact info | locations | site map investor relations | careers Company + Management - Vision and Values + Investor Relations + News and Media - Corporate Governance + Careers - History - New Ventures + Strategic Alliances + Community Relations Products Patients History In June 2003, Biogen and IDEC Pharmaceuticals announced their agreement to merge.
GPC-Biotech /* @import url(/css/styles.css);*/ @import url(/css/custom.css); @import url(/css/download.css); @import url(/css/styles.css); @import url(/css/custom.css); /* @import url(/css/styles_print.css);*/ Home Deutsch About the Company Anticancer Programs Technologies Investor Relations News &-Media Careers Calendar Contact/- Imprint Sitemap Search Glossary Forward Look-ing Statements...
author: Form+Fakten, Maximilian Vollendorf
3rdWorld 80.3% for Not yet met; on- going imatinib leukemia (CML) IFN- alfa/ cytarabine study (estimated completion 2009) Gastrointestinal stromal 2/ 1/ 02 Novartis PR: 38% Not yet met; ongoing tumors (GIST) studies CML in blast crisis, 5/ 10/ 01 Novartis Hematologic response (chronic phase): 88% Met accelerated phase, or in Hematologic response (accelerated chronic phase after failure phase)...
author: tracy
subject: 3rdWorld
3rdWorld page 9
author: tracy
subject: 3rdWorld
BIOPHARMA FDA Approvals - - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
Preview of the Society of Nuclear Medicine's 52nd Annual Meeting - Thomson Scientific Thomson.com - - - - - Advanced Search - - - EN : JP : CN : KR -- - - Thomson Scientific : Meeting Previews : 2005 : Preview of the Society of Nuclear Medicine's 52nd Annual Meeting PREVIEW OF THE SOCIETY OF NUCLEAR MEDICINE'S 52ND ANNUAL MEETING Date: 18-22 June 2005 Location: Toronto, ON, Canada Coverage Since its first meeting in May 1954, the Society of Nuclear Medicine (SNM) has...
BioPortfolio Limited Monoclonal Antibody Therapeutics - Current Market Dynamics & Future Outlook - 1.------ Executive Briefing - 2.------ Introduction - 2.1 --- Definition & Scope - 2.2---- Currently Marketed Monoclonal Antibody Therapeutics - 3.------ Market Size & Growth Rates - 3.1---- Global Market for Monoclonal Antibody Therapeutics - 3.2---- North American Market for Monoclonal Antibody...
Btech Investor Inc - News archive 2 - - - - BioNews BioWeb Companies Products BioReports - - - - - - Marketing approval for Biogen's (NASDAQ: BGEN) Amevive (alefacept) - treatment of moderate-to-severe chronic plaque psoriasis.
BioPortfolio Client Press Releases Site Map FDA to Initiate Study of HEMOLINK in Orthopedic Surgery Mediatum - Management Boutique at the Interface between Pharmaceutical and Biotech Industry Biotech Tracker News - Study Supports BioBypass Development Biotech Tracker News - Onyx’s Raf Inhibitor Shows Promise Biotech Tracker News - Boston Scientific Presents Additional Coated Stent Data Biotech Tracker News - Treatment...
FDA approved IDEC's (NASDAQ: IDPH) Zevalin (ibritumomab tiuxetan) - - - - BioNews BioWeb Companies Products BioReports - - - - - - FDA approved IDEC's (NASDAQ: IDPH) Zevalin (ibritumomab tiuxetan) Yesterday, the FDA approved IDEC's (NASDAQ: IDPH) Zevalin (ibritumomab tiuxetan) for marketing as part of the "Zevalin therapeutic regimen." Zevalin is a radioactive formulation of IDEC's successful...
BTECH REGULATORY RADAR - Tracking the Movement of Key Products Through Clinical Trials 25/2/02 - - - - BioNews BioWeb Companies Products BioReports - - - - - - BTECH REGULATORY RADAR - Tracking the Movement of Key Products Through Clinical Trials 25/2/02 FDA APPROVED IDEC's (NASDAQ: IDPH) Zevalin (ibritumomab tiuxetan) The FDA approved Zevalin for marketing as part of the "Zevalin therapeutic regimen." Zevalin is a radioactive formulation of...
Bad News for Corixa - - - - BioNews BioWeb Companies Products BioReports - - - - - Bad News for Corixa Corixa (NASDAQ: CRXA) received a major blow yesterday, announcing the receipt of a disapproving complete review letter from the FDA.Zevalin is now approved, Bexxar...
The Bexxar Saga Continues - - - - BioNews BioWeb Companies Products BioReports - - - - - The Bexxar Saga Continues Co-written by Gary Gamerman, President of Seraphim Life Sciences Consulting LLC, 703-242-5649, ggamerman@SeraphimLifeSciences.com.Zevalin (ibritumomab tiuxetan) had gained...
Biotech Tracker News - Advantages of the Zevalin Therapeutic Regimen IDEC’s (NASDAQ: IDPH ) Zevalin (ibritumomab tiuxetan) generated updated response duration data out of its 143-patient, randomized, Rituxan-controlled, phase III clinical trial for the treatment of relapsed or refractory low-grade, follicular, or transformed B cell non-Hodgkin lymphoma (NHL).
BioPortfolio BioNews (News & Press Releases) Jan to May 02 Betabloc Fails Due To Adverse Effects MOLECULAR DESIGN INTERNATIONAL AND LEADDISCOVERY ANNOUNCE STRATEGIC PARTNERSHIP 2nd Annual RETINAL DISEASE AND GLAUCOMA - New Therapeutic Strategies - BIOCHIPS 2002 - Technology Development & Application and BioChips- CAMBRIDGE ANTIBODY TECHNOLOGY ANNOUNCES KEY MANAGEMENT PROMOTIONS Evista May Have Cardiovascular Benefits in Some Patients Cubist...
Biogen Idec - Patient Stories Back to Top ZEVALIN ® (ibritumomab tiuxetan) Laura Colton Tepper Laura Colton Tepper, a paralegal at a large national law firm, was first diagnosed with low-grade non-Hodgkin’s lymphoma in 1996 at the age of 40.ZEVALIN.
Database I I - investigational drugs, therapies and vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products To purchase documents on-line click on- link attached to selected document!- The fee is $15 per document.
Database Z Z - investigational drugs, therapies and vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products To purchase documents on-line click on- -link attached to selected document!- The fee is $15 per document Documents are delivered by e-mail...
http://www.gene.com/gene/ir/financials/annual-reports/2003/financials/form10k.pdf UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D
http://www.gene.com/gene/ir/financials/annual-reports/2003/financials/form10k.pdf page 54
http://www.gene.com/gene/ir/financials/annual-reports/2003/financials/form10k.pdf page 12
